Medicines for Malaria Venture’s 7th African call for proposals for African scientist. Medicines for Malaria Venture’s (MMV) was launched on 3 November 1999, with initial seed finance of US$ 4 million from the Government of Switzerland, UK Department for International Development, the Government of the Netherlands, The World Bank and Rockefeller Foundation.
Their mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.
To be eligible for consideration for funding as part of this call, MMV welcomes proposals only from African scientists focused in the following priority areas:
- Compounds with confirmed activity on any antimalarial lifecycle stage
Novel molecules with confirmed activity (EC50 < 10uM) and a medicinal chemistry plan that tackles any known or anticipated liability. In line with MMV strategic goals, priority will be given to compounds with potential for optimization as drugs for chemoprevention with a human half-life >120h.
- Assay development and screening
Assay development and screening to support discovery or development of novel antimalarials.
- Computer-aided drug discovery
Use of computational approaches (cheminformatic and/or bioinformatic) to discover new molecules with predicted antimalarial activity or new antimalarial drug targets.
How to Apply for Medicines for Malaria Venture’s Proposal
- Please complete the African Letter of Interest template. Proposals involving a biological target should also include the target information template.
- See further instructions on how to complete the African Letter of Interest.
- The proposals funded as part of this call will have a project start date of 1 January 2025.
- All applications for any of the above must use the specified templates and should be sent electronically to [email protected] by Friday, 30 August 2024 at 12:00 pm (CEST).